Category Archives: Special Feature

American Oncology Network to be First Medical Oncology Network in United States to Offer THOR® Light Therapy at The Center for Cancer and Blood Disorders

New technology helps prevent oral mucositis for head and neck cancer patients undergoing radiation or chemoradiation

THE CENTER FOR CANCER AND BLOOD DISORDERS
Fort Myers, Fla. & Bethesda, Md., March 08, 2021 (GLOBE NEWSWIRE) — The Center for Cancer and Blood Disorders (CCBD), an American Oncology Network (AON) partner, is pleased to announce it is now offering THOR® Photobiomodulation (PBM) therapy for the prevention and treatment of mouth sores in cancer therapy patients. Patients can now receive light therapy at both office locations in Maryland, Bethesda at 6410 Rockledge Drive, Suite 660 and in Germantown at 19735 Germantown Road, Suite 255.

The positive effects of PBM therapy on oral mucositis have been reported in 42 randomized controlled trials and nine systematic reviews, reducing the incidence of severe mucositis. Guidelines issued by the Multinational Association … Continue reading

Posted in Industry, Special Feature, THE FUTURE OF LLLT | Leave a comment

James Carroll 2020 WALT Presidential Commendation

Thank you to The World Association for PhotobiomoduLation Therapy for the award today. As I said in my acceptance speech I am grateful for the many friends and good times I have enjoyed in the field of LLLT/PBM over the last 33 years, largely thanks to WALT. I should have said more about what I have learned from the many scientists, doctors, dentists, veterinarians, therapists, nurses and patients. It has led to an exciting, rewarding and fulfilling career, and I look forward to the next 40 years as we take PBM to where it is needed and belongs. So thank you WALT for giving me a life worth living.

Posted in James in Action, Special Feature | Leave a comment

West Virginia University Cancer Institute is using Photobiomodulation for their Oral mucositis patients

MONONGALIA COUNTY, W.Va (WDTV) – Cancer patients deal with many side effects when they go through treatment. The WVU Cancer Institute Department of Radiation Oncology found a way to prevent a side effect, known as mucositis, that is seen in head and neck cancer patients.

WVU Cancer Institute brings new technology to help with a common side effect

“It is an inflammation type of condition from head and neck radiation,” THOR photomedicine dental and oral mucositis specialist, Sara Jane Snyder said. “They get painful sores throughout their entire oral cavity, down their esophagus and all they down through their digestive track,” she said.

“Anybody who’s getting a high dose of chemoradiation treatment, it’s almost 100 percent guarantee that their going to get a high level of oral mucositis.”
Having mucositis can make everyday tasks difficult, like eating or brushing your teeth. This is why using what is called photobiomodulation helps treat this side effect.

“What we found … Continue reading

Posted in Industry, LLLT, Special Feature, THE FUTURE OF LLLT | Leave a comment

Seeing The Light

Written by Scot Faulkner

[Scot Faulkner advises global organizations and universities on healthcare reform and innovation. He served as the Chief Administrative Officer of the U.S. House of Representatives. He also served on the White House Staff, and as an Executive Branch Appointee.]

Imagine being successfully treated, painlessly and safely, for a wide range of diseases and conditions. Imagine having a cure for chronic pain.

This revolution in health and wellness is already available and will be celebrated on May 16 as the United Nations’ Annual International Day of Light.

On May 16, 1960, American physicist and engineer, Theodore Maiman, operated the first successful laser, achieving coherent and controllable light waves. This revolutionized manufacturing, communications, and health.

In 1967, Endre Mester in Semmelweis University Budapest, Hungary conducted studies to determine if lasers caused cancer. He shaved the hair from the bodies of mice, divided them into two groups and gave a laser treatment with a low powered ruby laser to one group. They did not get cancer. Instead the hair … Continue reading

Posted in Special Feature, THE FUTURE OF LLLT | Leave a comment

The story of how LLLT / Photobiomodulation was discovered

This is an extraordinary lecture. It is the story of how LLLT / Photobiomodulation was discovered, and because of the context in which it occurred you might also find it very moving, so get some tissues. It is an hour and 10 minutes long so get comfortable, maybe get some popcorn and a drink too. I will paste the email that Andrew Mester wrote into the comments section below.

Here is the email from Andrew Mester :

I had the privilege to give a keynote presentation at the most recent NAALT (North American Association of PhotobiomoduLation Therapy) meeting in February 5, 2017 in Coronado Island, San Diego. The title of paper was: “Invention of Laser Biostimulation”. My lecture is in Youtube now.

BACKGROUND:
Photo-medicine is an exciting new field in both scientific and clinical research all over the world and most recently in the USA. I learned in this interesting … Continue reading

Posted in Conference, Interviews, Special Feature | Leave a comment

Class IV laser dose concern. An update from Prof. Jan Bjordal. World Association for Laser Therapy (WALT)

The title of last months PMLS editorial was Low Level Laser Therapy (LLLT) and World Association for Laser Therapy (WALT) Dosage Recommendations. Written by the Scientific Secretary Prof. Jan Bjordal. He describes how far we have come and the importance of the WALT dosage recommendations. No abstract is available for editorials so I have prepared one for you below.

Posted in Rants, Special Feature | Leave a comment

LLLT for Multiple sclerosis (MS) : Nice work Jeri-Anne, Janis and Chukuka

Original article  from http://www.sciencecodex.com/light_as_medicine-121445

Multiple sclerosis (MS) causes progressive paralysis by destroying nerve cells and the spinal cord. It interrupts vision, balance and even thinking.

On a suggestion from a colleague, Jeri-Anne Lyons decided to test how the disease responded to a radical therapy – exposure to a certain wavelength of light called near-infrared (NIR).

Posted in Special Feature | 5 Comments